SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): December 6, 2005
Neurologix, Inc.
(Exact name of registrant as specified in its charter)
DELAWARE 0-13347 06-1582875
----------------------------------------------------------------------------
(State or other jurisdiction of (Commission I.R.S. Employer
incorporation or organization) File Number) Identification No.)
ONE BRIDGE PLAZA, FORT LEE, NEW JERSEY 07024
----------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
(201) 592-6451
-------------------------------------------------------------
(Registrant's telephone number,
including area code)
None
----------------------------------------------------------------
(Former name, former address and former fiscal year,
if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13(e)-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation of FD Disclosure
On December 6, 2005, Neurologix, Inc. issued a press release
announcing certain results of its gene therapy approach to epilepsy. A copy of
the press release is attached hereto as Exhibit 99.1 and incorporated herein by
reference.
The information, including the exhibit attached hereto, in this
Current Report is being furnished and shall not be deemed "filed" for the
purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or
otherwise subject to the liabilities of that Section. Such information shall
not be incorporated by reference into any registration statement or other
document pursuant to the Securities Act of 1933, as amended, except as
otherwise expressly stated in such filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
NEUROLOGIX, INC.
Date: December 6, 2005 By: /s/ Michael Sorell M.D.
Name: Michael Sorell, M.D.
Title: President and
Chief Executive Officer
EXHIBITS
99.1 Press release, dated December 6, 2005